Merck’s colorectal cancer therapy fails late-stage trial
Merck faces setback as Keytruda combination trials fail to expand cancer treatment ahead of patent loss
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Keytruda
Merck discontinues Phase 3 trial for lung cancer combo drug
When compared to patients in the control arm, patients in the vibostolimab and pembrolizumab fixed-dose combination arm…
FDA approved KEYTRUDA in combination with chemotherapy for adult patients with endometrial carcinoma
Approval marks the third FDA-approved indication for KEYTRUDA in endometrial carcinoma and the 40th indication for KEYTRUDA in the…
Merck discontinues Phase 3 KeyVibe-010 trial
The trial was discontinued after results showed that the coformulation of vibostolimab and pembrolizumab for treatment of resected…
GLP1 agonists set to become the best-selling drugs in 2024: GlobalData
Shift could reflect a changing demand away from oncology toward addressing metabolic disorders
DCGI approves KEYTRUDA to treat triple negative breast cancer, renal cell carcinoma
KEYTRUDA is now approved for 14 indications across eight tumour types in India
DCGI approves MSD India’s Keytruda for treating cervical and esophageal cancers
Keytruda is now approved for 10 indications in six different types of cancers in India
Amgen says Lumakras plus immunotherapy for lung cancer needs further study
The findings are the first indication of how well Lumakras works in combination with drugs that help the immune system attack…
Pfizer and BioNTech’s COVID-19 vaccine Comirnaty tops the list of best-selling drugs
Ends the nine-year reign of AbbVie’s Humira as the world’s best-selling pharma product
Nektar stops clinical trials for key cancer drug
The trials that Nektar stopped included those involving a combination of its drug Bempegaldesleukin with Bristol Myers Squibb Co’s…